Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Adenosine receptor antagonist (1) ·
Adenosine receptor antagonist; dopaminergic (1) ·
Adenosine receptor antagonist; phosphodiesterase inhibitor (1) ·
Alpha-adrenergic agonist; monoamine releaser (1) ·
Alpha-methylated amphetamine analogue; norepinephrine releasing agent (1) ·
AMPA modulator; catecholaminergic (1) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Dopamine and norepinephrine reuptake inhibitor (2) ·
Dopamine and serotonin reuptake inhibitor; actoprotector (1) ·
Dopamine reuptake inhibitor; tropane analogue (1) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
Indirect sympathomimetic; norepinephrine releaser (1) ·
Monoamine releasing agent (8) ·
Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Monoamine releasing agent; serotonergic at higher doses (1) ·
Monoamine reuptake inhibitor; sodium channel blocker (1) ·
N-methyl analogue of 2-AI (1) ·
Nicotinic acetylcholine receptor agonist (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine releaser (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Norepinephrine–dopamine reuptake inhibitor (2) ·
Potent dopamine and norepinephrine reuptake inhibitor (1) ·
Potent dopamine/norepinephrine reuptake inhibitor (1) ·
Selective norepinephrine reuptake inhibitor (1) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Trace amine-associated receptor 1 (TAAR1) agonist; monoamine releaser (1) ·
'"`UNIQ--vote-0000063C-QINU`"' Avoid in HFrEF (negative inotropy). CYP3A4 substrate AND moderate inhibitor — interacts substantially with statins (especially simvastatin), tacrolimus, cyclosporine, and many other CYP3A4 substrates'"`UNIQ--ref-0000063D-QINU`"'. (1)
uses:
None (43) ·
'"`UNIQ--vote-0000063E-QINU`"', '"`UNIQ--vote-0000063F-QINU`"', '"`UNIQ--vote-00000640-QINU`"', '"`UNIQ--vote-00000641-QINU`"' (1) ·
'"`UNIQ--vote-00000A66-QINU`"', '"`UNIQ--vote-00000A67-QINU`"', '"`UNIQ--vote-00000A68-QINU`"', '"`UNIQ--vote-00000A69-QINU`"', '"`UNIQ--vote-00000A6A-QINU`"' (1)
starting dose:
None (43) ·
ER 180-240 mg PO once daily; IR 30 mg PO QID; IV 0.25 mg/kg over 2 min for acute rate control, then 5-15 mg/h infusion (1) ·
IR 80-120 mg PO TID; ER 180-240 mg PO daily; IV 2.5-5 mg over 2 min for SVT termination (under monitoring); cluster prophylaxis up to 480-960 mg/d in divided doses (1)
preparations:
fda max:
routes:
onset:
halflife:
bioavailability:
pregnancy:
None (43) ·
Limited data; alternative antihypertensives generally preferred. Crosses placenta.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; labetalol/nifedipine generally preferred. Crosses placenta.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 45 results in range #1 to #45.